RxDoctor Payments Data

Kari Steinle, APRN

Nurse Practitioner · Overland Park, KSNPI 1225663263

Payments from drug & device makers

$2,725in general payments, 2019–2025

Across 99 payments — averaging $27.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Sumitomo Pharma America, Inc.$683
  • Astellas Pharma US Inc$457
  • AbbVie$375
  • Boston Scientific$60
  • Convatec Inc.$29
  • plus $67 from 3 others

What the payments were for

  • Travel & lodging$28711%
  • Food & beverage$2,23382%
  • Education$2047%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,725 in reported general payments places this provider in the 85th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$61,098
Medicare patients
306
Services billed
10,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron136$98,524
MyrbetriqMirabegron110$85,251
ElmironPentosan Polysulfate Sodium24$26,004
Estradiol206$13,116
PremarinEstrogens, Conjugated16$3,256
Tizanidine Hcl160$2,684
Clobetasol Propionate51$2,176
Amitriptyline Hcl109$1,573
Methenamine Hippurate29$1,515
Solifenacin Succinate36$1,408
Trimethoprim12$1,334
Estradiol (Twice Weekly)Estradiol12$1,186
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst107$1,133
Estradiol (Once Weekly)Estradiol12$779
Oxybutynin Chloride ErOxybutynin Chloride27$582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$683$98,524136 claims
Astellas Pharma US IncMyrbetriq$457$85,251110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →